News

Wed, 2012-11-07

Dyax Corp. to Participate in November 2012 Healthcare Conferences

BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in two upcoming conferences.

Gustav Christensen, President and Chief Executive Officer of Dyax, will present on Wednesday, November 14 at 11:20 AM (GMT), at the Jefferies 2012 Global Healthcare Conference, being held November 14-15, 2012 in London, England.

Mr. Christensen will also present at Piper Jaffray's 24th Annual Healthcare Conference, on Tuesday November 27 at 4:30 PM (ET). The conference is being held November 27-28, at The New York Palace Hotel in New York City.

At both events, Mr. Christensen will provide a corporate update regarding the Company's key value drivers — KALBITOR® (ecallantide) and the angioedema portfolio, as well as the Licensing and Funded Research Program (LFRP).

Both presentations will be webcast live and may be accessed by visiting the Investor Relations section of the company website at www.dyax.com. The webcasts will also be available on the Dyax website for a limited period of time following the conferences.

About Dyax

Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company's key value drivers are the KALBITOR® (ecallantide) business and the angioedema portfolio, as well as the Licensing and Funded Research Program (LFRP).

Dyax developed KALBITOR on its own and, since February 2010, the Company has been selling it in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Outside the United States, the Company has established partnerships to obtain regulatory approval for and commercialization of KALBITOR in certain markets and is evaluating opportunities in others.

The Company is currently developing products to expand its angioedema portfolio, including a diagnostic strategy to identify plasma kallikrein (bradykinin) mediated (PKM) angioedema and a therapeutic candidate, DX-2930, for the prophylactic treatment of PKM angioedema. KALBITOR and DX-2930 were identified using Dyax's patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the LFRP. This program has provided the Company a portfolio of product candidates being developed by its licensees, which currently includes 11 royalty and/or milestone bearing product candidates in various stages of clinical development, including three in Phase 3 trials.

Dyax is headquartered in Burlington, Massachusetts. For additional information about Dyax, please visit www.dyax.com. 

Teaser 4, 2nd row left, in news section

United We Stand Strong!

HAEi cares about you. We encourage patients to get organized - because "United We Stand Strong".

HAE International - Thumb 7HAE International - Thumb 7Become a National Member Organization (NMO). We are here to help you in founding a National Member Organization. Follow our step-by-step model. It doesn't have to be a difficult task creating the best foundation for patients in your country. Contact us for more information here


HAE International - Thumb 4HAE International - Thumb 4

Starting a National Patient Group (NPG). If you are interested in doing more around HAE - but don't feel that starting a full NMO is the right option here and now. You should maybe consider becoming a contact patient (NPG) for your country. Contact us here

Both NMO's and NPG's enjoy free membership of HAEi. Also we can help you host your country specific website under the global umbrella of HAEi.

Events

Fri, 2014-05-16 (All day)

2014 hae day :-)

On 16 May 2014 patient organizations throughout the globe will hold events, meetings, and fundraisers to support the global awareness day hae day :-)

..continue
Thu, 2014-05-15 12:00 - Sun, 2014-05-18 12:00

2014 HAE Global Conference

Venue: Hyatt Regency Reston, 1800 Presidents St., Reston, VA 20190, United States of America
Language: English

HAEi - International Patient Organization for C1 Inhibitor Deficiencies cordially invites you to attend the 2014 HAE Global Conference which will take place in Washington DC, 15 - 18 May 2014.

Registration for the conference is now open! Registration will take place on a first come, first serve basis – and since we again offer some extremely attractive registration rates and conditions, please do not wait too long registering for this exciting conference.

Please register here

..continue

Homepage Teaser 6, 2nd row right

HAE Global Community

Be part of the HAEi Community

HAEi is here to help you. Therefore we have created the HAEi Community that gives you all the bells and whistles you know from other social media (such as Facebook) and even a very sophisticated Forum, where you can discuss with fellow HAE patients and care givers. The only difference is - that here your information stays safe - and will only be shared with other HAE patients and care givers. If you are a HAE patient or directly related to a HAE patient we urge you to register today - and become an important member of our community

Help yourself and stay updated by registering already today - then you will be the first to know.....

Do you have Questions?
You can find answers on our FAQ-Page or
send us an e-mail to: info@haei.org
or go to the contact form page


Experiencing browser problems?

Our website is working properly on most web browsers. However, we know that the site will not perform correctly on Microsoft Internet Explorer version 6 and earlier! So if you are using Internet Explorer from Microsoft please ensure that you have version 7 or higher!


See the video from the 2012 HAE Global Conference in Copenhagen

Click here


HAEDAYHAEDAYLook out for next hae day :-) on 16 May 2014


www.haeday.org